Taro Pharmaceutical Industries

To see an up-to date selection of historical analyses and insights on Taro Pharmaceutical Industries, visit our new, dynamically updated Company Summary report pages for Taro Pharmaceutical Industries.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for Taro Pharmaceutical Industries are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on Taro Pharmaceutical Industries, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers
  Annual Sales WW - Sales Growth per Year (%)
  Rank Product Generic Name Pharmacological Class 2006 2007 2007
Taro Pharmaceutical Industries 1 Ovide malathion Pediculicide 28 32   14%  
  2 Clotrimazole & Betamethasone clotrimazole & betamethasone Imidazole & corticosteroid 16 16   0%  
  3 Warfarin Sodium warfarin sodium Vitamin K antagonist 20 15   (25%)  
 
  Note: Shaded Cells  

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers
 
  Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current)
Taro Pharmaceutical Industries - Gabapentin Central Nervous System Anti-epileptics GABA agonist Filed
  - T2001 Central Nervous System Other CNS drugs Non-sedating barbiturate Pre-clinical
  - T2000 Central Nervous System Other CNS drugs Non-sedating barbiturate Phase III

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers
Taro Pharmaceutical Industries
  2005 2006
 Valuation Measures
  Based on Latest Share Prices
     Valuing the Equity
       Market Capitalisation 346 346
       PE Ratio (diluted) - Normalised (x) 48.9 (2.7)
 
     Valuing the Enterprise
       Enterprise Value 403 403
       Free Cash Flow (Pre-Dividends) (28) (80)
       FCF Yield (%) (6.9%) (19.8%)
 
 Forecast Financials
  Income Statement
     Total Revenues 298 184
     Cost of Goods Sold (129) (142)
     S,G & A (108) (97)
     R&D (46) (36)
     Other Income/ Expense - Net 0 -
     EBIT - Normalised 15 (91)
     Net Interest & Financial Items (8) (13)
     Pre-tax Profits - Normalised 7 (104)
     Exceptionals - (38)
     Income Before Taxes 7 (142)
     Tax (2) 2
     Tax Rate (%) 22.2% 1.2%
     Net Income - Reported 6 (141)
     Net Income - Normalised 6 (103)
 
  Per Share Data
     EPS - Diluted 0.19 (4.77)
     EPS - Basic 0.19 (4.80)
     EPS - Normalised (diluted) 0.19 (3.48)
     EPS - Normalised (basic) 0.19 (3.50)
     Avg. Shares Outstanding - Diluted 29.3 29.5
     Avg. Shares Outstanding - Basic 29.3 29.3
     DPS 0.00 -

NEWS - Selected Product News Headlines (as of 11 June 2008)
Taro Receives Final FDA Approval for RX Cetirizine Hydrochloride Syrup ANDA   (Taro Pharmaceutical Industries)   23-Jun-2008
Taro Receives Final FDA Approval for Cetirizine Hydrochloride Oral Solution ANDA   (Taro Pharmaceutical Industries)   22-Apr-2008
Taro Receives Tentative FDA Approval for Lamotrigine Tablets ANDA   (Taro Pharmaceutical Industries)   03-Apr-2008
Taro Receives FDA Approval for Ondansetron Hydrochloride Injection USP, 2 mg/mL ANDA   (Taro Pharmaceutical Industries)   25-Mar-2008
Taro Receives FDA Approval of New Drug Application for Flo-Pred(TM) (Prednisolone Acetate Oral Suspension)   (Taro Pharmaceutical Industries)   22-Jan-2008

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON
 
  Product Generic Name
Taro Pharmaceutical Industries A/T/S erythromycin
  Acetazolamide acetazolamide
  Alclometasone Dipropionate alclometasone
  Alustra hydroquinone
  Amiodarone Hydrochloride amiodarone
  Ammonium Lactate ammonium lactate
  Betamethasone Dipropionate betamethasone
  Carbamazepine carbamazepine
  Carvedilol carvedilol
  Cetirizine Hydrochloride cetirizine
  Ciclopirox Olamine ciclopirox
  Ciclopirox Topical Solution ciclopirox
  Ciprofloxacin ciprofloxacin
  Citalopram citalopram
  Clindamycin clindamycin
  Clobetasol Propionate clobetasol propionate
  Clomipramine clomipramine
  Clorazepate clorazepate
  Clotrimazole clotrimazole
  Clotrimazole & Betamethasone clotrimazole & betamethasone
  Dermovate clobetasol propionate
  Desonide desonide
  Desoximetasone desoximetasone
  Diflorasone Diacetate diflorasone diacetate
  Econazole Nitrate econazole
  ElixSure acetaminophen, ibuprofen, pseudoephedrine
  Enalapril Maleate enalapril
  Enalapril/HCTZ enalapril & hydrochlorothiazide
  Etodolac etodolac
  Etopan XL etodolac
  Flo-Pred prednisolone
  Fluconazole fluconazole
  Fluocinonide fluocinonide
  Fluorouracil fluorouracil
  Fluticasone Propionate fluticasone propionate
  Gabapentin gabapentin
  Halobetasol Propionate halobetasol propionate
  Hydrocortisone Butyrate hydrocortisone butyrate
  Ketoconazole ketoconazole
  Lamotrigine lamotrigine
  Loratadine Syrup loratadine
  Lustra hydroquinone
  Lustra-AF hydroquinone
  Meloxicam meloxicam
  Metronidazole Topical Gel metronidazole
  Miconazole 3-Day Vaginal Cream miconazole
  Mometasone Furoate mometasone furoate
  Mupirocin Ointment mupirocin
  Nystatin nystatin
  Ondansetron ondansetron
  Ovide malathion
  Oxcarbazepine oxcarbazepine
  Phenytoin phenytoin
  Primsol trimethoprim
  Ranitidine Syrup ranitidine
  T2000 -
  T2001 -
  Tarodent Mouthwash chlorhexidine
  Terbinafine Cream terbinafine
  Terconazole terconazole
  Topicort desoximetasone
  Triamcinolone Acetonide triamcinolone acetonide
  U-cort hydrocortisone
  Warfarin Sodium warfarin sodium

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.